share_log
Breakings ·  Jun 11 20:06
Annovis Bio Inc: Annovis Bio Is Planning an 18-Month Phase III Trial Focusing on Biomarker-Positive Early Ad Patients
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment